Top Stories
The oral tyrosine kinase inhibitor was previously approved as a second-line treatment for metastatic HER2-positive breast cancer.
The FDA nod for symptomatic dermographism adds to the BTK inhibitor's earlier approval in chronic spontaneous urticaria.
The higher dose of solengepras significantly reduced the average daily OFF time compared with placebo at week 12.
The Dutch patent court of the Hague determined that the subcutaneous (SC) formulation of Keytruda (pembrolizumab) infringes one of Halozyme's patents around its MDASE technology.
Clinical studies of the oral T-cell modulator MPT-062, which stems from the biotech's Advanced Covalent Exploration (ACE) platform, are expected to begin next year.
Conference News
75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline69% expect access to capital to improve, yet 79% identify investor risk aversion a...
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indicationsBIO-Europe provides a key platform to advance ongoing d...
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS ...
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients li...
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and remibr...
